ZOM
(NYSE)
0.1577
-0.0010  (-0.63%)
Volume (24h): 25.66M Day Range: 0.1540 - 0.1620
Market Cap: 26.26M 52W Range: 0.1121 - 0.4990
May-29-20 08:05PM Zomedica Pharmaceuticals Corp. Closes $20 Million Public OfferingGlobeNewswire
May-27-20 02:16AM Zomedica Pharmaceuticals Corp. Announces $20 Million Public OfferingGlobeNewswire
May-20-20 08:05PM Zomedica Completes Verification of Three More Assays for its TRUFORMA™ Point-of-Care Diagnostic PlatformGlobeNewswire
May-11-20 10:55PM Zomedica Pharmaceuticals Corp (ZOM) Reports Q1 Loss, Lags Revenue EstimatesZacks
08:20PM Zomedica Announces First Quarter 2020 Financial ResultsGlobeNewswire
Apr-21-20 10:55AM Zomedica Completes Verification of its TRUFORMA™ Point-of-Care Diagnostic Platform and the First Assay, Canine total T4GlobeNewswire
Apr-13-20 11:15PM Zomedica Provides Corporate UpdateGlobeNewswire
Apr-08-20 03:32AM Zomedica Pharmaceuticals Corp. Announces Pricing of $4.0 Million Public OfferingGlobeNewswire
Apr-07-20 08:01PM Zomedica Pharmaceuticals Corp. Announces Public OfferingGlobeNewswire
Feb-26-20 10:25PM Zomedica Pharmaceuticals Corp. Announces Year End 2019 Financial ResultsGlobeNewswire
Feb-14-20 09:15PM Zomedica Announces Completion of $2.5 Million Registered Direct OfferingGlobeNewswire
Feb-12-20 01:43PM Zomedica Announces $2.5 Million Registered Direct OfferingGlobeNewswire
Feb-11-20 11:55AM Zomedica Files U.S. Patent Application for Fecal Parasite DetectionGlobeNewswire
Jan-30-20 11:55AM Zomedica to Voluntarily Delist its Common Shares from TSX Venture Exchange Effective February 10, 2020GlobeNewswire
Jan-23-20 11:55AM Zomedica to Focus on TRUFORMA™ CommercializationGlobeNewswire
Jan-20-20 11:55AM Zomedica Successfully Completes Development and Manufacturing Milestones for its Cancer Liquid Biopsy PlatformGlobeNewswire
Dec-23-19 09:00PM Hedge Funds Have Never Been This Bullish On Zomedica Pharmaceuticals Corp. (ZOM)Insider Monkey
Dec-03-19 11:55AM Zomedica Announces Management ChangesGlobeNewswire
Nov-13-19 11:55AM Zomedica Expands ZM-006 Pilot Efficacy StudyGlobeNewswire
Nov-12-19 09:53PM Zomedica Announces Third Quarter 2019 Financial ResultsGlobeNewswire
Nov-05-19 09:15PM Zomedica Announces 2019 Annual Meeting ResultsGlobeNewswire
Oct-31-19 10:55AM Zomedica Commences Final TRUFORMA™ Diagnostic Verification StudyGlobeNewswire
Oct-03-19 03:27PM CORRECTION FROM SOURCE: Zomedica Pushes TRUFORMA(TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics MarketNewsfile
Oct-01-19 01:17PM Zomedica Pushes TRUFORMA (TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics MarketNewsfile
Sep-18-19 05:39PM Do Insiders Own Shares In Zomedica Pharmaceuticals Corp. (CVE:ZOM)?Simply Wall St.
Sep-17-19 10:55AM Zomedica names Dr. Stephanie Morley PresidentGlobeNewswire
Sep-11-19 01:09PM PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.Newsfile
01:00PM Zomedica to Present at the Fall Investor Summit on Monday, September 16 in New York CityACCESSWIRE
Sep-03-19 10:55AM Zomedica to Present at RHK Capital 2019 Disruptive Growth Conference, Fall Investor Summit, and Sidoti & Company Fall 2019 Investor ConferenceGlobeNewswire
Aug-19-19 10:55AM Animal Health Veteran Johnny D. Powers Joins Zomedica Board of DirectorsGlobeNewswire
Aug-13-19 12:00PM Zomedica Inc. Prepares to Launch Veterinarian Diagnostic Device, TRUFORMA(TM); Has Potential to Change Diagnostic Landscape in Animal Health (NYSE American: ZOM)ACCESSWIRE
Aug-08-19 08:08PM Zomedica Announces Second Quarter 2019 Financial ResultsGlobeNewswire
Aug-07-19 10:55AM Zomedica Announces TRUFORMA™ Assay Updates and R&D ExpansionGlobeNewswire
Jul-25-19 10:55AM Zomedica’s Dr. Bonnie Bragdon to Speak at AVMA Convention 2019 on Sunday, August 4GlobeNewswire
Jul-17-19 10:55AM Zomedica Announces Initiation of a Digital Data Platform Enhancing its Diagnostic PipelineGlobeNewswire
Jun-26-19 02:05PM ZOM: One Instrument; Multiple SolutionsZacks Small Cap Research
Jun-13-19 10:55AM Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy PlatformGlobeNewswire
Jun-12-19 08:35PM Zomedica to Present at Raymond James Life Sciences and MedTech ConferenceGlobeNewswire
Jun-10-19 10:00AM Zomedica Announces $7 Million Second Tranche Closing of Preferred SharesGlobeNewswire
May-21-19 10:55AM Zomedica Announces Achievement of Product Development Milestones on its TRUFORMA™ Point-of-Care Diagnostic PlatformGlobeNewswire
May-10-19 09:21PM Zomedica Announces First Quarter 2019 Financial ResultsGlobeNewswire
10:00AM Zomedica Announces Private Placement of Preferred SharesGlobeNewswire
Mar-26-19 10:00AM Zomedica Pharmaceuticals Corp. Announces Pricing of $3 Million Underwritten Public Offering of Common SharesGlobeNewswire
Mar-25-19 08:01PM Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering of Common SharesGlobeNewswire
Mar-05-19 11:55AM Zomedica Initiates ZM-006 Pilot Efficacy Study and Provides Corporate UpdatesGlobeNewswire
Feb-26-19 09:05PM Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial ResultsGlobeNewswire
Jan-15-19 11:55AM Zomedica Appoints Dr. Bonnie Bragdon as Vice President of Veterinary AffairsGlobeNewswire
Jan-14-19 11:55AM Zomedica Announces $4.28 Million Private Placement Closing and Corporate UpdateGlobeNewswire
Dec-20-18 10:23PM Zomedica Provides Update on Pipeline Development and Announces At-The-Market Offering ProgramGlobeNewswire
Nov-28-18 02:53PM Qorvo, Zomedica Tie-Up to Enhance Vet Health with BAW SensorsZacks
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)